Pamela Ng1, Suzanne Murray2, Sean M Hayes2. 1. AXDEV Group Inc., 210-8, Place du Commerce, Brossard, QC, Canada J4W 3H2. Electronic address: ngp@axdevgroup.com. 2. AXDEV Group Inc., 210-8, Place du Commerce, Brossard, QC, Canada J4W 3H2.
Abstract
INTRODUCTION: The introduction of several new disease-modifying therapies (DMTs) to the field of Multiple Sclerosis (MS) treatment requires that MS healthcare providers have a comprehensive understanding of the implications of each new treatment option in order to select the treatment that best suits their patient. An international study was conducted in 6 countries to obtain a better understanding of the issues and challenges experienced by Neurologists and Nurses in the treatment and management of their patients with MS. The goal of this research was to obtain evidence to inform future Continuing Medical Education (CME) initiatives and health policies that promote knowledge translation to clinical practice. This article focuses on challenges reported in relation to the use of newly approved therapies, in light of the risks of these new treatments, as well as screening and monitoring precautions that must be taken. MATERIALS AND METHODS: An exploratory study and literature review informed the design of an IRB-approved online survey deployed to MS Neurologists and Nurses practicing in 6 countries (Germany, France, Italy, Spain, UK, USA). RESULTS: The sample consisted of actively practicing Neurologists (n=156) and Nurses (n=153). Substantive challenges were reported in participant's knowledge of and confidence in three categories: i) safety profile of newly approved therapies, ii) screening patients for treatment with newly approved therapies, and iii) monitoring for serious adverse events. DISCUSSION AND CONCLUSION: Findings indicate that, internationally, healthcare providers report substantive challenges integrating newly approved therapies into their clinical decision-making. This study highlights potential factors underlying the challenges, and identifies important targets for CME interventions and policymakers to enhance clinical decision-making amongst MS providers.
INTRODUCTION: The introduction of several new disease-modifying therapies (DMTs) to the field of Multiple Sclerosis (MS) treatment requires that MS healthcare providers have a comprehensive understanding of the implications of each new treatment option in order to select the treatment that best suits their patient. An international study was conducted in 6 countries to obtain a better understanding of the issues and challenges experienced by Neurologists and Nurses in the treatment and management of their patients with MS. The goal of this research was to obtain evidence to inform future Continuing Medical Education (CME) initiatives and health policies that promote knowledge translation to clinical practice. This article focuses on challenges reported in relation to the use of newly approved therapies, in light of the risks of these new treatments, as well as screening and monitoring precautions that must be taken. MATERIALS AND METHODS: An exploratory study and literature review informed the design of an IRB-approved online survey deployed to MS Neurologists and Nurses practicing in 6 countries (Germany, France, Italy, Spain, UK, USA). RESULTS: The sample consisted of actively practicing Neurologists (n=156) and Nurses (n=153). Substantive challenges were reported in participant's knowledge of and confidence in three categories: i) safety profile of newly approved therapies, ii) screening patients for treatment with newly approved therapies, and iii) monitoring for serious adverse events. DISCUSSION AND CONCLUSION: Findings indicate that, internationally, healthcare providers report substantive challenges integrating newly approved therapies into their clinical decision-making. This study highlights potential factors underlying the challenges, and identifies important targets for CME interventions and policymakers to enhance clinical decision-making amongst MS providers.
Authors: Kevin N Alschuler; Annette Wundes; Dennis W Dietrich; Bojan Boskovski; Igor Kuzmanovski; Katharine S Alexander; Gloria von Geldern; Gary A Stobbe Journal: Neurology Date: 2016-07-05 Impact factor: 9.910
Authors: Kevin N Alschuler; Gary A Stobbe; Deborah P Hertz; Kurt L Johnson; Gloria von Geldern; Annette Wundes; Piper Reynolds; Kent Unruh; John D Scott Journal: Int J MS Care Date: 2019 Jul-Aug
Authors: Rafael Arroyo; Angel P Sempere; Elena Ruiz-Beato; Daniel Prefasi; Agata Carreño; Montse Roset; Jorge Maurino Journal: BMJ Open Date: 2017-03-08 Impact factor: 2.692
Authors: Marco Kaufmann; Jens Kuhle; Milo A Puhan; Christian P Kamm; Andrew Chan; Anke Salmen; Jürg Kesselring; Pasquale Calabrese; Claudio Gobbi; Caroline Pot; Nina Steinemann; Stephanie Rodgers; Viktor von Wyl Journal: Mult Scler J Exp Transl Clin Date: 2018-12-06